Clinical Trial Update: A Gene Delivery Study to Evaluate the Safety and Expression of Delandistrogene Moxeparvovec in Participants Under the Age of Four With Duchenne Muscular Dystrophy (DMD) [Phase 2]

View source ↗

Summary

This clinical trial update shows Roche's delandistrogene moxeparvovec being studied in children under four with Duchenne Muscular Dystrophy in Phase 2, with the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• Delandistrogene moxeparvovec (delandistrogene moxeparvovec)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Duchenne Muscular Dystrophy | Phase 2 | Status: ACTIVE_NOT_RECRUITING